Levenberg Shulamit, Zoldan Janet, Basevitch Yaara, Langer Robert
Department of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa 32000, Israel.
Blood. 2007 Aug 1;110(3):806-14. doi: 10.1182/blood-2006-08-019190. Epub 2007 Apr 5.
Growing interest in using endothelial cells for therapeutic purposes has led to exploring human embryonic stem cells as a potential source for endothelial progenitor cells. Embryonic stem cells are advantageous when compared with other endothelial cell origins, due to their high proliferation capability, pluripotency, and low immunogenity. However, there are many challenges and obstacles to overcome before the vision of using embryonic endothelial progenitor cells in the clinic can be realized. Among these obstacles is the development of a productive method of isolating endothelial cells from human embryonic stem cells and elucidating their differentiation pathway. This review will focus on the endothelial potential of human embryonic stem cells that is described in current studies, with respect to the differentiation of human embryonic stem cells to endothelial cells, their isolation, and their characterization.
将内皮细胞用于治疗目的的兴趣日益浓厚,这促使人们探索将人类胚胎干细胞作为内皮祖细胞的潜在来源。与其他内皮细胞来源相比,胚胎干细胞具有优势,因为它们具有高增殖能力、多能性和低免疫原性。然而,在临床中使用胚胎内皮祖细胞的设想得以实现之前,有许多挑战和障碍需要克服。这些障碍包括开发一种从人类胚胎干细胞中分离内皮细胞并阐明其分化途径的有效方法。本综述将聚焦于当前研究中所描述的人类胚胎干细胞的内皮潜能,涉及人类胚胎干细胞向内皮细胞的分化、它们的分离以及特性。